Top Biotechs at ASCO: Ying Huang on Carvykti’s 5-Year Data and Expanding CAR-T Therapy in Myeloma

In this episode of Top Biotechs at ASCO, Ying Huang, CEO of Legend Biotech, a leader in cell therapy innovation. Ying shares exciting five-year data for Carvykti (cilta-cel), Legend’s CAR-T therapy for relapsed/refractory multiple myeloma, presented at ASCO 2025. Legend’s latest results from the CAR-2.1 study show unprecedented outcomes: ✅ One-third of patients remain progression-free five years after a single infusion. ✅ Median overall survival extended to 60 months. ✅ Deep responses with MRD negativity in many patients. #TopBiotechsAtASCO #LegendBiotech #Carvykti #MultipleMyeloma #CellTherapy #CAR_T #ASCO2025 SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information. Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research. 🔔 New videos every day! 💻 Visit us at https://oncodaily.com/